|Day Low/High||65.76 / 68.49|
|52 Wk Low/High||65.76 / 109.98|
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
Celgene Corporation (NASDAQ:CELG) today announced initial safety data from its ongoing proof-of-concept trial of JCARH125 in patients with relapsed/refractory multiple myeloma.
Celgene Corporation (NASDAQ: CELG) today announced results of the phase 3 AUGMENT study, which showed that REVLIMID ® (lenalidomide) in combination with rituximab (R 2) demonstrated superior progression-free survival (PFS) in patients with...
bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with...
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from the pivotal, phase 3 MEDALIST trial evaluating the efficacy and safety of investigational luspatercept to treat patients with ring sideroblast (RS+)...
Celgene Corporation (NASDAQ: CELG) today announced initial data from the dose-escalation part of an ongoing, open-label multicenter phase 1/2 study of investigational lisocabtagene maraleucel (liso-cel; JCAR017) in patients with relapsed/refractory...
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a pivotal, phase 3 trial (BELIEVE) evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated...
Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.
Celgene could be at a temporary low or it could be starting a new base pattern.
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies' lead investigational anti-BCMA CAR T cell therapy candidate for patients with...
What comes next? Anything concrete to justify this rally? Sorry, says Jim Cramer. It's just a reprieve, not a sustainable turnaround.
I tire of hearing that there has been a correction.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
NEW YORK, Nov. 14, 2018 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, announced it is joining forces with Celgene (NASDAQ: CELG) to...
Jim Cramer explains his post-election play book: Growth stocks may be the way to go.
Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor events where Celgene management will provide an overview of the Company.
Celgene Corporation (NASDAQ:CELG) today announced that data from more than 100 abstracts, including a study being featured as a plenary presentation and more than 40 selected for oral presentations, evaluating Celgene investigational agents and...
It becomes difficult for me to tell you where to run in these markets...
Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,890 million for the third quarter of 2018, an 18 percent increase from the same period in 2017.
Jim Cramer takes a closer look at Lululemon Athletica, Celgene, McDonald's, Red Robin Gourmet Burgers, Apple Hospitality REIT.
This is serious: The market is ignoring legitimate, positive earnings, says Jim Cramer, and tariffs and rates are the culprits.
Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.
TV host and fashion journalist Louise Roe launches the INSIDE PERSPECTIVE campaign with Celgene Corporation (NASDAQ: CELG) and Otezla ® (apremilast), and for the first time, shares her inside story with psoriasis, a condition she has been living with for...
Celgene Corporation (NASDAQ: CELG) today announced results from an open-label phase II/III National Clinical Trials Network (NCTN) study led by the ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute (NCI), part of the National...
Celgene Corporation (NASDAQ:CELG) today announced the appointment of Dr. Alise Reicin to President, Global Clinical Development, reporting to Mark J.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.